Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mometasone/Formoterol FDC in Moderate to Severe COPD
NCT00383435Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Oct 2006
- Primary completion
- Jul 2010
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of mometasone and formoterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Organon & Co. Primary endpoints: Area Under the Forced Expiratory Volume in One Second Concentration Time Curve from 0 to 12 hours and Morning Predose Forced Expiratory Volume in One Second at 13 weeks. Started Oct 2006; status: completed.
02
Drugs
mometasoneformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00383435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383435.